Vital Therapies Inc (VTL) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $-0.31 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.37. During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Vital Therapies Inc. Company shares were Reiterated by Canaccord Genuity on Mar 9, 2016 to “Buy”, Firm has raised the Price Target to $ 10 from a previous price target of $8 .
Vital Therapies Inc closed down -0.02 points or -0.24% at $8.31 with 33,442 shares getting traded on Friday. Post opening the session at $8.28, the shares hit an intraday low of $8.07 and an intraday high of $8.39 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Oct 27, 2015, John Michael Dunn (General Counsel and Secretary) purchased 9,385 shares at $6.88 per share price. According to the SEC, on Oct 27, 2015, Cheryl Cohen (director) purchased 3,500 shares at $7.17 per share price. On Sep 11, 2015, Jean Jacques Bienaime (director) purchased 14,000 shares at $3.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Vital Therapies Inc. is a biotherapeutic company. The Company is focused on developing a cell-based therapy targeting treatment of all forms of acute liver failure. The Company’s product candidate the ELAD System is an extracorporeal bio-artificial liver therapy. ELAD System utilizes VTL C3A cell bank which contains human liver-derived cells that can be grown in almost unlimited quantities stored and shipped across the world. The Company is conducting clinical trials involving the ELAD System including its VTI-208 a Phase III clinical trial in subjects with alcohol-induced liver decompensation (AILD); a second Phase III clinical trial for subjects with severe acute alcoholic hepatitis (SAAH) and a Phase II clinical trial for subjects with fulminant hepatic failure (FHF) and surgery-induced acute liver failure (SILF).